MINNEAPOLIS, Dec. 19,
2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH), a leader in automated platforms for biotherapeutic
characterization, today announced a co-marketing and co-promotion
agreement with Waters Corporation aimed at expanding the reach of
advanced biotherapeutic characterization and development processes.
The companies plan to combine their complementary expertise on
charge separation (Bio-Techne's MauriceFlex™ System) and liquid
chromatography mass spectrometry (BioAccord™ LC-MS System from
Waters) to deliver innovative solutions that optimize workflows,
improve precision, and accelerate development timelines.
Scientists and commercial team members from both companies
participated in several joint activities in October and
November 2024, including the
publication of an application note, a webinar, poster
presentations, and talks at key conferences including CASSS MS,
Festival of Biologics and PEGS EU, and in-person talks at two
Bio-Techne User Group Meetings in Boston and San
Diego. Moving forward, application scientists from both
companies are working on the analysis of additional classes of
biomolecules and plan to exhibit the joint results in a poster at
upcoming scientific conferences. This work will guide application
notes, webinars, and presentations at upcoming Bio-Techne User
Group Meetings to co-market each company's advanced biotherapeutic
characterization and development process capabilities.
"We are thrilled to see how these new workflows are accelerating
biotherapeutic characterization in biopharma labs," said
Will Geist, President of the Protein
Sciences Segment at Bio-Techne. "Our goal is to continue offering
innovative solutions that empower scientists, streamline workflows,
and help bring life-saving therapies to market faster."
Explore Bio-Techne's automated biotherapeutic characterization
platforms here.
Learn about Waters innovative analytical solutions here.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH)
is a global life sciences company providing innovative tools and
bioactive reagents for the research and clinical diagnostic
communities. Bio-Techne products assist scientific investigations
into biological processes and the nature and progress of specific
diseases. They aid in drug discovery efforts and provide the means
for accurate clinical tests and diagnoses. With hundreds of
thousands of products in its portfolio, Bio-Techne generated
approximately $1.2 billion in net
sales in fiscal 2024 and has approximately 3,100 employees
worldwide. For more information on Bio-Techne and its brands,
please visit https://www.bio-techne.com or follow the Company
on social media at: Facebook, LinkedIn, Twitter or
YouTube.
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
BioAccord is a trademark of Waters Technologies
Corporation.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-biotherapeutic-characterization-strategic-co-marketing-and-co-promotion-agreement-302335808.html
SOURCE Bio-Techne Corporation